ClinicalTrials.gg
Enrolling by invitationNCT06443463Updated May 1, 2026

Long-term Safety and Tolerability of BHV-7000

A Phase 2 interventional study of BHV-7000 and BHV-7000 in Focal Epilepsy, sponsored by Biohaven Therapeutics Ltd.. Enrolling by invitation at 283 sites in 27 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
660
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Planned enrollment
4th of 86
660 · median 100
Started
2024
with 5 others
Phase 2
23 of 102
4 open now
Primary completion
2026-12
later than 3 of 22 live
Registered
91st of 102
by date
Lead sponsor
3 of 102
Biohaven Therapeutics Ltd.

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 4th largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2024, is one of 23 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 91st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

03

Conditions studied

  • Focal Epilepsy

Keywords

  • Focal Epilepsy
  • Epilepsy
  • Seizure
  • Refractory Epilepsy
  • Partial Epilepsy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects who completed the double-blind phase (DBP) of prior parent study, BHV7000-302 or BHV7000-303.
  • (FOCBP) Females of Child Bearing Potential must have a negative urine pregnancy test at the Baseline/Day 0 visit

Key Exclusion Criteria:

  • Any condition, such as an ongoing AE with/without sequelae, or is poorly tolerating IP in the double-blind phase of the parent study, that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator.
  • Any medical condition, based on the judgement of the Investigator, that would confound the ability to adequately assess safety and efficacy outcome measures
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    BHV-7000 50 mg

    Drug: BHV-7000

  • Experimental
    BHV-7000 75 mg

    Drug: BHV-7000

Interventions

  • BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily

  • BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs

    To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.

    Time frame: Up to 104 weeks

  2. Number of Subjects with Clinically Significant Laboratory Abnormalities

    To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.

    Time frame: Up to 104 weeks

07

Study locations

283 sites

Showing the first 100 of 283 sites across 27 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Jul 30, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06443463
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Jul 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opakalim

Start the discussion